Technical Analysis for RGS - Regeneus Ltd  

Grade Last Price % Change Price Change
grade F 0.058 -3.33% -0.002
RGS closed down 3.33 percent on Monday, February 24, 2020, on 1.68 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical RGS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 20 DMA Bearish -3.33%
MACD Bearish Signal Line Cross Bearish -3.33%
New 52 Week Closing Low Bearish -3.33%
Wide Bands Range Expansion -3.33%
Gapped Down Weakness -3.33%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Interactive chart


Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.
Biotechnology Cancer Biology Life Sciences Stem Cells Cancers Regenerative Medicine Cell Biology Induced Stem Cells Mesenchymal Stem Cell Therapeutic Products Immunotherapy Stem Cell Therapy

Is RGS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.22
52 Week Low 0.058
Average Volume 136,484
200-Day Moving Average 0.093
50-Day Moving Average 0.077
20-Day Moving Average 0.067
10-Day Moving Average 0.062
Average True Range 0.004
ADX 26.36
+DI 24.956
-DI 48.682
Chandelier Exit (Long, 3 ATRs ) 0.067
Chandelier Exit (Short, 3 ATRs ) 0.071
Upper Bollinger Band 0.079
Lower Bollinger Band 0.055
Percent B (%b) 0.12
BandWidth 36.066
MACD Line -0.004
MACD Signal Line -0.004
MACD Histogram -0.0002
Fundamentals Value
Market Cap 12.12 Million
Num Shares 209 Million
EPS 0.02
Price-to-Earnings (P/E) Ratio 3.63
Price-to-Sales 2.70
Price-to-Book 3.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.061
Resistance 3 (R3) 0.061 0.061 0.061
Resistance 2 (R2) 0.061 0.060 0.061 0.060
Resistance 1 (R1) 0.059 0.059 0.059 0.059 0.060
Pivot Point 0.059 0.059 0.059 0.059 0.059
Support 1 (S1) 0.057 0.058 0.057 0.057 0.056
Support 2 (S2) 0.057 0.057 0.057 0.056
Support 3 (S3) 0.055 0.057 0.056
Support 4 (S4) 0.055